Detecting and understanding combinatorial mutation patterns responsible for HIV drug resistance

We propose a systematic approach for a better understanding of how HIV viruses employ various combinations of mutations to resist drug treatments, which is critical to developing new drugs and optimizing the use of existing drugs. By probabilistically modeling mutations in the HIV-1 protease or reverse transcriptase (RT) isolated from drug-treated patients, we present a statistical procedure that first detects mutation combinations associated with drug resistance and then infers detailed interaction structures of these mutations. The molecular basis of our statistical predictions is further studied by using molecular dynamics simulations and free energy calculations. We have demonstrated the usefulness of this systematic procedure on three HIV drugs, (Indinavir, Zidovudine, and Nevirapine), discovered unique interaction features between viral mutations induced by these drugs, and revealed the structural basis of such interactions.

[1]  Ronald M. Levy,et al.  Pairwise and higher-order correlations among drug-resistance mutations in HIV-1 subtype B protease , 2009, BMC Bioinformatics.

[2]  H. Gunthard,et al.  Update of the Drug Resistance Mutations in HIV-1. , 2008, Topics in HIV medicine : a publication of the International AIDS Society, USA.

[3]  N. Ghoraf Reliability formula & limit law of the failure time of “m-consecutive-k-out-of-n:F system” , 2008 .

[4]  Thomas Lengauer,et al.  Bioinformatics prediction of HIV coreceptor usage , 2007, Nature Biotechnology.

[5]  Jun S. Liu,et al.  Bayesian inference of epistatic interactions in case-control studies , 2007, Nature Genetics.

[6]  Takeaki Uno,et al.  Mining complex genotypic features for predicting HIV-1 drug resistance , 2007, Bioinform..

[7]  Soo-Yon Rhee,et al.  HIV-1 protease and reverse transcriptase mutations for drug resistance surveillance , 2007, AIDS.

[8]  R. Shafer,et al.  Genotypic predictors of human immunodeficiency virus type 1 drug resistance , 2006, Proceedings of the National Academy of Sciences.

[9]  J. Louis,et al.  Kinetic, stability, and structural changes in high-resolution crystal structures of HIV-1 protease with drug-resistant mutations L24I, I50V, and G73S. , 2006, Journal of molecular biology.

[10]  Irene T Weber,et al.  Crystal structures of HIV protease V82A and L90M mutants reveal changes in the indinavir-binding site. , 2004, European journal of biochemistry.

[11]  B. J. Betts,et al.  HIV-1 protease and reverse transcriptase mutation patterns responsible for discordances between genotypic drug resistance interpretation algorithms. , 2003, Journal of acquired immune deficiency syndromes.

[12]  Thomas Lengauer,et al.  Diversity and complexity of HIV-1 drug resistance: A bioinformatics approach to predicting phenotype from genotype , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[13]  Robert W. Shafer,et al.  Genotypic Testing for Human Immunodeficiency Virus Type 1 Drug Resistance , 2002, Clinical Microbiology Reviews.

[14]  A. D. Clark,et al.  The Lys103Asn mutation of HIV-1 RT: a novel mechanism of drug resistance. , 2001, Journal of molecular biology.

[15]  S. Deeks Nonnucleoside Reverse Transcriptase Inhibitor Resistance , 2001 .

[16]  J. Fantini,et al.  Mutation L210W of HIV-1 reverse transcriptase in patients receiving combination therapy. Incidence, association with other mutations, and effects on the structure of mutated reverse transcriptase. , 2000, Journal of biomedical science.

[17]  N. Sluis-Cremer,et al.  Molecular mechanisms of HIV-1 resistance to nucleoside reverse transcriptase inhibitors (NRTIs) , 2000, Cellular and Molecular Life Sciences CMLS.

[18]  R. Hameed,et al.  Amprenavir: a new human immunodeficiency virus type 1 protease inhibitor. , 2000, Clinical therapeutics.

[19]  J. Falloon,et al.  Drug resistance during indinavir therapy is caused by mutations in the protease gene and in its Gag substrate cleavage sites , 1997, Journal of virology.

[20]  J. Mellors,et al.  Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor , 1996, Journal of virology.

[21]  E. Arnold,et al.  An in vivo mutation from leucine to tryptophan at position 210 in human immunodeficiency virus type 1 reverse transcriptase contributes to high-level resistance to 3'-azido-3'-deoxythymidine , 1996, Journal of virology.

[22]  P. Harrigan,et al.  Significance of amino acid variation at human immunodeficiency virus type 1 reverse transcriptase residue 210 for zidovudine susceptibility , 1996, Journal of virology.

[23]  J. Condra,et al.  In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors , 1995, Nature.

[24]  Huldrych F Günthard,et al.  Update of the drug resistance mutations in HIV-1: Spring 2008. , 2008, Topics in HIV medicine : a publication of the International AIDS Society, USA.

[25]  Tommy F. Liu,et al.  Surfing The Web: Web Resources for HIV Type 1 Genotypic-Resistance Test Interpretation , 2006 .

[26]  Bryan Chan,et al.  Human immunodeficiency virus reverse transcriptase and protease sequence database , 2003, Nucleic Acids Res..

[27]  Robert W. Shafer,et al.  Human Immunodeficiency Virus Reverse Transcriptase and Protease Sequence Database , 1999, Nucleic Acids Res..